BioLineRx

BioLineRx Gross Profit

The Gross Profit of BioLineRx (BLRX) as of Oct 18, 2026 is 430,387.00 USD. In the previous year, Gross Profit was 19.68 M USD — a change of -97.81% (lower).

Gross Profit

430,387.00USD

YoY

-97.81%

Last updated:

Gross Profit of BioLineRx is 2025 430,387.00 USD. Gross Profit of BioLineRx was 2024 19.68 M USD. It decreases by -97.81% lower compared to the previous year.

The BioLineRx Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2018
-451,000.00 USD
Jan 1, 2019
-940,000.00 USD
Jan 1, 2020
-934,000.00 USD
Jan 1, 2021
-702,000.00 USD
Jan 1, 2022
-654,000.00 USD
Jan 1, 2023
1.11 M USD
Jan 1, 2024
19.68 M USD
Jan 1, 2025
430,387.00 USD
The BioLineRx Gross Profit history
YEARGross ProfitYoY
430,387.00USD-97.81%
19.68 MUSD+1,675.90%
1.11 MUSD-269.42%
-654,000.00USD-6.84%
-702,000.00USD-24.84%
-934,000.00USD-0.64%
-940,000.00USD+108.43%
-451,000.00USD-6.17%
-480,675.00USD-0.25%
-481,888.00USD+9.30%
-440,893.00USD+64.29%
-268,366.00USD-100.28%
94.46 MUSD+2.59%
92.07 MUSD+120.80%
41.70 MUSD+68.91%
24.69 MUSD+145.26%
10.07 MUSD-1,682.19%
-636,178.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioLineRx Revenue

BioLineRx Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
4.80 M USD
-58.47 M USD
-60.61 M USD
Jan 1, 2024
28.94 M USD
-1.92 M USD
-9.22 M USD
Jan 1, 2025
1.19 M USD
-1.89 M USD
-1.18 M USD
Jan 1, 2026 (e)
1.62 M USD
2.30 M USD
-13.66 M USD
Jan 1, 2027 (e)
2.22 M USD
2.89 M USD
-10.97 M USD
Jan 1, 2028 (e)
7.84 M USD
2.87 M USD
-1.41 M USD
Jan 1, 2029 (e)
7.40 M USD
1.74 M USD
-2.61 M USD
Jan 1, 2030 (e)
17.26 M USD
2.89 M USD
-1.39 M USD

BioLineRx Margins

BioLineRx stock margins

The BioLineRx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioLineRx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioLineRx.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
23.08 %
-1,218.13 %
-1,262.79 %
Jan 1, 2024
67.99 %
-6.64 %
-31.86 %
Jan 1, 2025
36.19 %
-158.58 %
-99.58 %
Jan 1, 2026 (e)
36.19 %
141.72 %
-843.15 %
Jan 1, 2027 (e)
36.19 %
130.23 %
-493.72 %
Jan 1, 2028 (e)
36.19 %
36.62 %
-18.03 %
Jan 1, 2029 (e)
36.19 %
23.55 %
-35.30 %
Jan 1, 2030 (e)
36.19 %
16.76 %
-8.07 %

BioLineRx Stock analysis

What does BioLineRx do? BioLineRx Ltd. is a biopharmaceutical company based in Hevel Modi'in, Israel, developing therapeutics for oncology and rare diseases. Its pipeline includes GLIX1 for glioblastoma and other cancers, APHEXDA for sickle cell disease and pancreatic cancer, and BL-5010 for non-surgical skin lesion removal. The company, incorporated in 2003, is listed on the market since 2011 and employs 20 people. BioLineRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioLineRx stock

Gross Profit of BioLineRx is 430,387.00 USD in 2025.

Gross Profit of BioLineRx changed from 19.68 M USD to 430,387.00 USD, representing a -97.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit BioLineRx since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's BioLineRx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BioLineRx

All Key Metrics — BioLineRx